---
title: 'Perspectives on drug development in chronic myelomonocytic leukemia: changing
  the paradigm'
date: '2024-11-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39509115/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241113193346&v=2.18.0.post9+e462414
source: Blood
description: 'Drug development for chronic myelomonocytic leukemia (CMML) has failed
  to parallel the recent success observed in related myeloid neoplasms. To address
  these shortcomings, the US Food and Drug Administration (FDA) held a "Mini-symposium
  on CMML: Current State of the Art and Trial Design" in September 2023. This symposium
  brought together a panel of key FDA regulators and academic experts in CMML drug
  development to discuss challenges and provide perspectives on future drug development
  for ...'
disable_comments: true
---
Drug development for chronic myelomonocytic leukemia (CMML) has failed to parallel the recent success observed in related myeloid neoplasms. To address these shortcomings, the US Food and Drug Administration (FDA) held a "Mini-symposium on CMML: Current State of the Art and Trial Design" in September 2023. This symposium brought together a panel of key FDA regulators and academic experts in CMML drug development to discuss challenges and provide perspectives on future drug development for ...